RealFeedApp beta

Usona secured FDA priority voucher for its psilocybin candidate PSIL201

The race to win the first FDA nod for a classic psychedelic is intensifying, with Usona Institute reportedly filing for approval ahead of the field leader Compass Pathways.

Field
drugs and trials
What they did
Researchers at Usona Institute launched phase III clinical trials for their psilocybin-based drug to treat treatment-resistant depression and secured an expedited review from the FDA.
Why it matters
This could change the market for psychedelic drugs, as Usona, a company previously low-profile, might become the first to receive FDA approval for a classic psychedelic.
#psilocybin#fda#usona institute#depression#clinical trial

Read the original →